Endogenous Slo1 level was also decreased after CRBN was knocked down by RNAi or knocked out by CRISPR-Cas9 gene editing in glioma cells (Fig 4E and 4F; S4G Fig). This evidence concerns the gene CRBN and central nervous system cancer.